News

Enrollment of the first patient is expected this month. Werner Tschollar, chief medical officer of Xytis, said: “We are working with the London School of Hygiene and Tropical

Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting. If approved for marketing, the drug

The first study involved 75 patients in a variety of chronic conditions associated with neuropathic pain and demonstrated a statistically significant improvement in pain compared to placebo as

The phase I trial is being conducted in the US and will include up to 50 patients with advanced solid tumors and lymphoma who have either failed standard

The nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist NBI-56418 was assessed over 12 weeks in women with endometriosis, a condition which happens when tissue similar to the endometrial lining

The biopharmaceutical company said that the trial endpoints were the time to systemic disease progression and the change in velocity of Prostate Specific Antigen levels. Neither endpoint was

The committee evaluated the first ten patients enrolled to the phase II trial of PDX in patients with relapsed or refractory peripheral T-cell lymphoma who had completed one

The agreement will use Ablynx’ Nanobodies, a novel class of therapeutic proteins which combine the beneficial features of conventional antibodies, with desirable properties of small-molecule drugs. In addition,

The acquisition includes brand names such as Carbolevure, Revitalose, Balsoclase and Toclase, representing annual sales of approximately $18 million. UCB will continue to manufacture and supply some of